News > Press Releases

Hua Medicine – Recap of ADA 79th Scientific Sessions

– 2019-06-20
June 20, 2019

At last week’s American Diabetes Association’s 79th Scientific Sessions, Hua Medicine, a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, presented data from an enzyme kinetics study differentiating dorzagliatin from other glucokinase activators, and preliminary data on unbiased machine learning clustering analysis.

The enzyme kinetics study poster presentation included results from five GKAs which advanced into phase II clinical studies, some of which suffered from hypoglycemia, and others lack of durable efficacy in T2D patients. The study provides insight to some key properties contributing to development of a GKA that repairs the glucose sensor function and remodels glucose homeostasis.

The unbiased clustering analysis poster presentation utilizes Hua Medicine’s lead compound, dorzagliatin’s phase II data. Using an unsupervised clustering analysis, six subtypes of T2D were identified based on clinically relevant biomarkers. This suggests that T2D patients can be differentiated using a hyperdimensional clustering framework, and supports the potential of using dorzagliatin in combination with other anti-diabetic agents for personalized T2D care in the future.

In addition, the Company was also featured in four videos on ADA TV this year, broadcast at the convention center, conference related hotels, and on YouTube. The four videos include: (1) Glucokinase: 50 Years of Research; (2) A New Kind of Glucokinase Activator; (3) Patient First: Clinical Trials in China; and (4) A Global Effort to Stop Diabetes. The videos cover the history and science behind dorzagliatin, as well Hua’s effort in ensuring quality in our clinical trials.

Links to ADA TV Videos:

About Dorzagliatin

Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetics. By addressing the defect of the glucose sensor function of glucokinase, or GK, dorzagliatin has the potential to repair the impaired glucose homeostasis state of Type 2 diabetics and serve as a first-line standard of care therapy for the treatment of Type 2 diabetes, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.

About Hua Medicine
Hua is a leading, clinical stage innovative drug development company in China focused on novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 Diabetes into NDA enabling stage and started 2 Phase III trials in China. The Company has also initiated product life-cycle management studies of this novel diabetes drug, and advanced its use in personalized diabetes care. Hua's strategy is to leverage the cost-efficient and high-quality drug development capabilities available in China, while working very closely with disease experts and regulatory agencies in China and rest of the world to advance diabetes care solutions for global patients.

For additional information please contact:
Hua Medicine
Emily Yeh

Copyright © 2019 Hua Medicine, All Rights Reserved